Table 5.

Correlation of clinicopathological characteristics with SETD2 expression in patients with PDA

Characteristic	Estimate for decrease SETD2 score a	SE	p value
Tumour site: head vs body/tail	−31.4	18.7	0.098
Jaundice	−15.1	14.6	0.304
Weight loss	2.3	13.6	0.867
Abdominal pain	11.4	13.4	0.397
Preoperative diabetes	−3.5	15.6	0.822
BMI (kg/m2)	2.2	1.1	0.045 b
Smoking (pack-years)	0.17	0.33	0.619
Alcohol use: heavy vs low/moderate	−29.2	22.5	0.200
Serum CA19-9	0.0003	0.0046	0.944
Total bilirubin	−1.83	0.95	0.058
Alkaline phosphatase	−0.030	0.013	0.026 b
Tumour size	1.1	4.5	0.810
Clinical stage (AJCC8)
Overall difference			0.637
Stage III/IV vs stage I/IIA	21.1	22.4	0.350
Stage IIB vs stage I/IIA	11.2	16.9	0.511
Stage III/IV vs stage IIB	9.9	18.7	0.599
Tumour grade
Overall difference			0.600
G1 vs G2	−12.3	18.7	0.514
G1 vs G3	−20.8	20.5	0.315
G2 vs G3	−8.5	15.8	0.592
Lymph node metastases present	2.5	14.7	0.864
Perineural invasion present	13.4	13.4	0.320
Angiolymphatic invasion present	−7.5	13.2	0.571
Common bile duct extension present	−10.0	13.5	0.459
Peripancreatic extension present	8.9	17.6	0.614
Duodenal extension present	−18.1	13.0	0.169
Neoadjuvant treatment	17.5	16.9	0.303

^aEstimate of effect for decrease in SETD2 score.

^bp<0.05.

AJCC8, American Joint Committee on Cancer 8th edition cancer staging manual; BMI, body mass index; CEA, carcinoembryonic antigen; PDA, pancreatic ductal adenocarcinoma; SE, standard error.